Transforming Medication Access: Using Technology and FDA’s New NDA Pathway Empowers Patient Options

FDA’s new ACNU (Additional Condition for Nonprescription Use) NDA pathway permits use of technology to transform medication access, offering a consumer-focused, equitable approach that meets diverse needs.

In December 2024, FDA finalized the ACNU NDA regulatory pathway, introducing an additional route for patient medication access. This pathway offers a tailored approach, while aligning with individual medical needs and circumstances. An ACNU drug may include validated technology interfaces, instead of healthcare provider prescriptions, to determine if self-directed consumer access to the drug is appropriate without a prescription. Consumers requiring greater clinical scrutiny will continue to require a prescription. ACNU drugs are nonprescription because eligible consumers do not require a provider interaction, however, they are not OTC because specific criteria or "condition(s)" must be met, thus maintaining safeguards for appropriate patient selection and use.

The ACNU pathway creates an opportunity for sponsors to develop novel mechanisms for medication access that are activated when a consumer completes a necessary ACNU "condition" that ensures only appropriate patients can access the medication, in the nonprescription setting. Grounded in digital technology, potential solutions enable more personalized and flexible access, expanding options for consumers while ensuring safety and efficacy. By reducing barriers, the ACNU framework has the potential to improve the consumer experience, health equity and public health.

Key Benefits
1. Increased Consumer Engagement: Digital access empowers consumers to take greater control and ownership of their healthcare decisions
2. Enhanced Health Equity: The ACNU pathway addresses unmet needs by providing new access routes, especially where provider/pharmacy access is limited.
3. Co-Marketing Potential: ACNU drugs, distinguished by specific “condition(s)” which create a meaningful difference, may be co-marketed with traditional prescription NDAs, broadening access and facilitating increased utilization.
4. Public Health: By expanding appropriate access, this new pathway promotes better health outcomes through reduced barriers, greater efficiency and inclusivity.